Skip to contentC
Collegium Pharmaceutical, Inc
C
COLLCollegium Pharmaceutical, Inc Q2 2023 · 10-Q
Revenue$135.55M$135.55M+9.7% vs Q2 2022 Net Income$13.01M$13.01MN/M vs Q2 2022 EPS Diluted$0.34$0.34N/M vs Q2 2022 Gross Profit$73,826,000+41.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Collegium Pharmaceutical, Inc · CIK 1267565 · Engraved from SEC EDGAR
Operating Cash Flowderived$99,722,000+146.5% Free Cash Flowderived$99,666,000+149.2% Margins · derivedGross margin54.5%+12.1 pt vs Q2 2022
Operating margin26.3%+17.3 pt vs Q2 2022
Net margin9.6%+13.8 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 3, 2023 · 34 d after period end